Clinical Trials Logo

Hereditary Angioedema (HAE) clinical trials

View clinical trials related to Hereditary Angioedema (HAE).

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04583007 No longer available - Clinical trials for Hereditary Angioedema (HAE)

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Start date: n/a
Phase:
Study type: Expanded Access

The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent angioedema attacks. This expanded access program enables these participants with a high unmet medical need to continue receiving lanadelumab during the interim period between completion of either the SHP643-301 (NCT04070326; SPRING study) or the TAK-743-3001 (NCT04444895) study and potential licensure of lanadelumab for the respective age group and/or treatment.